| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
90,000,000 |
| Market
Cap: |
1.51(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7 - $25.34 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
53 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,013 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
14,367 |
60,451 |
398,445 |
| Total Sell Value |
$0 |
$132,462 |
$726,464 |
$8,176,008 |
| Total People Sold |
0 |
5 |
10 |
12 |
| Total Sell Transactions |
0 |
5 |
11 |
35 |
| End Date |
2025-09-11 |
2025-06-10 |
2024-12-10 |
2023-12-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gustafson Kurt A |
Director |
• • – |
2025-06-16 |
4 |
AS |
$9.22 |
$27,595 |
D/D |
(2,993) |
20,183 |
|
36% |
|
| Feigal Ellen |
Director |
• • – |
2025-06-16 |
4 |
AS |
$9.22 |
$27,595 |
D/D |
(2,993) |
19,183 |
|
36% |
|
| Ranieri Richard J |
Director |
• • – |
2025-06-16 |
4 |
AS |
$9.22 |
$27,595 |
D/D |
(2,993) |
19,183 |
|
36% |
|
| Montgomery Alan Bruce |
Director |
• • – |
2025-06-16 |
4 |
AS |
$9.22 |
$20,422 |
D/D |
(2,215) |
20,611 |
|
36% |
|
| Gorman Kevin Charles |
Director |
• • – |
2025-06-16 |
4 |
AS |
$9.22 |
$29,255 |
D/D |
(3,173) |
18,905 |
|
36% |
|
| Gustafson Kurt A |
Director |
• • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
13,686 |
23,176 |
|
- |
|
| Feigal Ellen |
Director |
• • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
13,686 |
22,176 |
|
- |
|
| Simpson Todd E |
Director |
• • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
13,686 |
13,686 |
|
- |
|
| Ranieri Richard J |
Director |
• • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
13,686 |
22,176 |
|
- |
|
| Klencke Barbara |
Director |
• • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
13,686 |
19,672 |
|
- |
|
| Montgomery Alan Bruce |
Director |
• • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
13,686 |
22,826 |
|
- |
|
| Gorman Kevin Charles |
Director |
• • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
13,686 |
22,078 |
|
- |
|
| Valente Nancy |
EVP, Chief Development Officer |
• • – |
2025-05-02 |
4 |
S |
$11.03 |
$50,914 |
D/D |
(4,616) |
49,169 |
|
25% |
|
| Cornelissen Bart Jan |
SR. VICE PRESIDENT & CFO |
• • – |
2025-04-10 |
4 |
S |
$8.06 |
$30,233 |
D/D |
(3,750) |
61,348 |
|
5% |
|
| Valente Nancy |
EVP, Chief Development Officer |
• • – |
2025-03-10 |
4 |
S |
$13.60 |
$34,877 |
D/D |
(2,565) |
53,785 |
|
34% |
|
| Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2025-03-10 |
4 |
S |
$13.60 |
$268,080 |
D/D |
(19,716) |
465,419 |
|
34% |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• • – |
2025-03-10 |
4 |
S |
$13.60 |
$131,851 |
D/D |
(9,697) |
236,574 |
|
34% |
|
| Eckert Celia |
SVP, GENERAL COUNSEL |
• • – |
2025-03-10 |
4 |
S |
$13.60 |
$78,047 |
D/D |
(5,740) |
63,507 |
|
34% |
|
| Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2025-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
109,745 |
485,135 |
|
- |
|
| Cornelissen Bart Jan |
SR. VICE PRESIDENT & CFO |
• • – |
2025-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
21,949 |
65,098 |
|
- |
|
| Eckert Celia |
SVP, GENERAL COUNSEL |
• • – |
2025-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
21,949 |
69,247 |
|
- |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• • – |
2025-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
29,851 |
246,271 |
|
- |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• • – |
2025-02-03 |
4 |
OE |
$15.69 |
$55,574 |
D/D |
3,542 |
216,420 |
|
- |
|
| Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2025-02-03 |
4 |
OE |
$15.69 |
$138,198 |
D/D |
8,808 |
375,390 |
|
- |
|
| Montgomery Alan Bruce |
Director |
• • – |
2024-12-04 |
4 |
AS |
$27.03 |
$38,406 |
D/D |
(1,421) |
9,140 |
|
-64% |
|
316 Records found
|
|
Page 1 of 13 |
|
|
0.87 (4.92%) 
